Eton Pharmaceuticals (NASDAQ:ETON) Issues Quarterly Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) posted its quarterly earnings data on Tuesday. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02), Zacks reports. The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Eton Pharmaceuticals Stock Down 4.0 %

Shares of ETON stock opened at $14.68 on Wednesday. The company has a 50 day moving average of $15.45 and a 200-day moving average of $11.42. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $18.41. The firm has a market cap of $382.43 million, a P/E ratio of -66.73 and a beta of 1.37.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.